Track market-moving stories before they get noisy

EUR/JPY resumed by breaking through 176.19 last week. Initial bias stays on the downside this week with focus on 175.26/41 support zone. Strong rebound from there, followed by firm break of 177.95 resistance will indicate short term bottoming. However, sustained break of 175.26/41 will carry larger bearish implications. Next target is 100% projection of 186.00 to 177.82 from 181.53 at 173.35.

In the bigger picture, price action from 187.93 is seen as a corrective pattern to up trend from 154.77 (2025 low). Strong support should be seen from 175.41 cluster support (2025 high) and 38.2% retracement of 154.77 to 187.93 at 175.26 to contain downside. However, decisive break will raise the chance of larger bearish reversal and target 61.8% retracement at 167.43.

In the long term picture, as long as 175.41 resistance turned support holds, up trend from 94.11 (2021 low) is still expected to resume through 187.93 at a later stage. However, considering bearish divergence condition in M MACD, firm break of 175.41 will argue that a major top is already in place, and target 55 M EMA (now at 163.51).

ActionForex

ActionForex.com was set up back in 2004 with the aim to provide insightful analysis to forex traders, serving the trading community for two decades. We started providing only a daily and a mid-day report, now known as Action Insights. Gradually, we added a lot more in-house contents to the site. Technical Outlook section was expanded to cover more pairs. In addition to that, Top Movers, Heat Map, Pivot Point Charts and Pivot Meters, Action Bias and Volatility Charts, are tools used by traders from all over the world.

USD/CHF’s fall from 0.8394 extended to 0.8190 last week but recovered. Initial bias is turned neutral this week first. Below 0.8190 will target 38.2% retracement of 0.7603 to 0.8394 at 0.8092. On the upside, above 0.8629 minor resistance will turn intraday bias back to the upside for stronger rebound.

In the bigger picture, rise from 0.7603 should at least be reversing the medium term trend. Focus is on 0.8332 support turned resistance (2023 low) for confirmation. Firm break there will target 61.8% retracement of 0.9200 (2025 high) to 0.7603 at 0.8590. For now, this will remain the favored case as long as 0.7948 support holds.

In the long term picture, price action from 0.7065 (2011 low) are seen as a corrective pattern to the multi-decade down trend from 1.8305 (2000 high). It’s uncertain if the fall from 1.0342 is the second leg of the pattern, or resumption of the downtrend. But in either case, outlook will stay bearish as long as 55 M EMA (now at 0.8571) holds.

ActionForex

ActionForex.com was set up back in 2004 with the aim to provide insightful analysis to forex traders, serving the trading community for two decades. We started providing only a daily and a mid-day report, now known as Action Insights. Gradually, we added a lot more in-house contents to the site. Technical Outlook section was expanded to cover more pairs. In addition to that, Top Movers, Heat Map, Pivot Point Charts and Pivot Meters, Action Bias and Volatility Charts, are tools used by traders from all over the world.

Sofetabart mipitecan (Sofe-M) in combination with bevacizumab demonstrated a 79% confirmed objective response rate and 100% disease control rate, with similar activity observed across FRα expression levels

Clinical activity with Sofe-M was maintained even in patients with prior PARP inhibitor exposure, patients who typically experience poor outcomes with platinum-based chemotherapy

Sofe-M is currently being studied in both platinum-sensitive and platinum-resistant ovarian cancer in multiple Phase 3 studies as part of the FRAmework-01 master protocol

, /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced new Phase 1 data showing that its investigational folate receptor alpha (FRα) antibody-drug conjugate (ADC) sofetabart mipitecan (Sofe-M) plus bevacizumab achieved a confirmed objective response rate (cORR) of 79% and a disease control rate (DCR) of 100% in patients with platinum-sensitive ovarian cancer (PSOC). A cORR of 79% or higher was seen in both poly (ADP-ribose) polymerase inhibitor (PARPi)-treated and PARPi-naïve patients. These data will be shared in an oral presentation at the European Society for Medical Oncology (ESMO) Annual Congress in Madrid, Spain.

FRα is expressed in almost all ovarian cancers, at much higher levels than in healthy tissue, making it a target that can help direct treatment to tumor cells. Sofe-M is an FRα-targeting ADC composed of an Fc-silent, FRα-specific humanized monoclonal antibody linked to exatecan, a topoisomerase I inhibitor, via a proprietary cleavable polysarcosine linker. The antibody is designed to bind FRα on the surface of tumor cells, delivering exatecan directly into the tumor cell to disrupt DNA replication.

Jacob Van Naarden, Executive Vice President and President of Lilly Oncology: "The standard of care for platinum-sensitive ovarian cancer has remained unchanged for a decade and demands new treatment options. Results for Sofe-M show a promising efficacy and tolerability profile across both platinum-resistant and platinum-sensitive ovarian cancer, regardless of FRα expression levels or prior treatment. These data give us confidence as we continue to study Sofe-M in our Phase 3 FRAmework-01 program to bring this potential new medicine to the women who need it."

The Phase 1 study is evaluating Sofe-M plus bevacizumab in patients with advanced solid tumors, including a cohort of 33 women with PSOC who received Sofe-M (4 mg/kg) plus bevacizumab (15 mg/kg). Patients received a median of three prior systemic regimens (range 1–6), including prior PARPi (67%) and prior bevacizumab (70%). As of the July 6, 2026, data cutoff, the cORR among the 29 patients with measurable disease was 79.3% (23/29; 6 complete responses [CR, 20.7%] and 17 partial responses [PR, 58.6%]), and DCR was 100%. Responses were consistent across FRα expression levels and prior PARPi exposure. Median duration of response (DOR) and median progression-free survival (PFS) were not reached at median follow-ups of 6.2 and 10.2 months, respectively.

Chrisann Kyi, MD, Gynecologic Medical Oncologist & Early Drug Development Specialist at Memorial Sloan Kettering Cancer Center: "The durable and robust responses we've seen in patients with platinum-sensitive ovarian cancer are important, particularly in a PARPi pretreated population, where the response rate seen with Sofe-M exceeds what has been reported in published platinum re-challenge studies. The observed safety profile and low discontinuation rates, combined with early efficacy results, support the continued investigation of Sofe-M as a potentially meaningful new option for patients."

Sofe-M plus bevacizumab demonstrated a safety profile consistent with the known profiles of each medicine. No new safety signals were observed. The most common treatment-emergent adverse events (TEAEs) across all patients included epistaxis (73%), nausea (73%), anemia (58%), neutropenia (55%), and fatigue (52%). The most common Grade ≥3 TEAEs were neutropenia (42%) and anemia (24%); febrile neutropenia occurred in 3% of patients, and G-CSF prophylaxis was not mandated. Any-grade neuropathy occurred in 9% of patients, with no Grade ≥3 events. Dose reductions occurred in 42% of patients, and 6% discontinued treatment due to an adverse event.

The FRAmework-01 program is evaluating Sofe-M in three global Phase 3 trials across both platinum-resistant and platinum-sensitive ovarian cancer: Part A tests Sofe-M as monotherapy in platinum-resistant disease; Part B tests Sofe-M plus bevacizumab in platinum-sensitive disease that progressed on or within six months of completing a PARPi; and Part C tests Sofe-M plus bevacizumab in PARPi-naïve platinum-sensitive disease. The study is being conducted in partnership with the European Network for Gynaecological Oncological Trial groups (ENGOT - lead groups GINECO/NOGGO e.V.), the GOG Foundation (GOG), and the Asia-Pacific Gynecologic Oncology Trials Group (APGOT).

For more information on Lilly's oncology pipeline, click here.

Frequently Asked Questions

What is sofetabart mipitecan (Sofe-M)? Sofetabart mipitecan (Sofe-M) is an investigational folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC) being studied for the treatment of ovarian cancer and other solid tumors. It is designed to selectively bind to cancer cells expressing FRα and deliver a topoisomerase I inhibitor payload directly to those cells. What is an antibody-drug conjugate? An antibody-drug conjugate (ADC) is a type of medicine that pairs an antibody with a cell-killing payload. The antibody is designed to recognize and bind to a specific protein found on the surface of cancer cells, and the payload is released once the ADC reaches its target, allowing the medicine to attack cancer cells while limiting exposure to healthy tissue.1 How is Sofe-M different from other FRα-targeted ADCs? Sofe-M is designed to target FRα across a broad range of expression levels, including in tumors with lower FRα expression. In this Phase 1 study, Sofe-M plus bevacizumab showed a confirmed objective response rate of 79.3% in platinum-sensitive ovarian cancer (PSOC), with consistent activity across FRα expression levels and regardless of prior PARP inhibitor exposure. Earlier studies in platinum-resistant ovarian cancer (PROC) also demonstrated responses observed across all FRα expression levels and in patients previously treated with mirvetuximab soravtansine (MIRV).2 These results are being further evaluated in Lilly's ongoing Phase 3 FRAmework-01 program, which is studying Sofe-M across both platinum-resistant and platinum-sensitive ovarian cancer. What are the results with sofetabart mipitecan (Sofe-M) in the treatment of platinum-sensitive ovarian cancer (PSOC)?The Phase 1 study demonstrated encouraging clinical activity, including a confirmed objective response rate (cORR) of 79.3% and a disease control rate (DCR) of 100%, in heavily pretreated patients with platinum-sensitive ovarian cancer. Activity was observed across FRα expression levels and regardless of prior PARP inhibitor exposure. Median duration of response (DOR) and median progression-free survival (PFS) were not reached at median follow-ups of 6.2 and 10.2 months, respectively. Sofetabart mipitecan (Sofe-M) plus bevacizumab demonstrated a safety profile consistent with the known profiles of each medicine, with no new safety signals observed and a low rate of discontinuation due to adverse events (6%). These findings support continued investigation of Sofe-M in the ongoing Phase 3 FRAmework-01 trial. In this study Sofe-M was dosed at 4 mg/kg. Why is it dosed at 3mg/kg in the Phase 3 FRAmework-01 trial? The 3 mg/kg dose of Sofe-M was selected as the recommended phase 3 dose (RP3D), based on analysis of the safety, efficacy and PK data as monotherapy. The ORR was comparable between the two doses, with ORRs of 59.0% (95% CI 42.1, 74.4) and 58.8% (95% CI 32.9, 81.6), at 4 mg/kg and 3mg/kg doses, respectively. Safety signals were higher at 4 mg/kg versus 3 mg/kg, with Grade ≥3 TRAEs at 56.4% vs 35.3% and dose reductions of 41.0% vs 23.5%. What are historical clinical trial results for standard of care in platinum-sensitive ovarian cancer (PSOC)? For patients who recur after platinum-based chemotherapy and PARP inhibitor (PARPi) maintenance, published real world data on subsequent platinum re-challenge have shown modest response rates, with an objective response rate (ORR) of 41.9%.3 Other studies of platinum-based regimens, such as OCEANS, were conducted prior to the routine use of PARPi maintenance and did not include patients previously treated with a PARPi,4 a population that now represents a majority of patients with recurrent PSOC, including those enrolled in Sofe-M's Phase 1 study. What is platinum-sensitive ovarian cancer (PSOC)? Platinum-sensitive ovarian cancer (PSOC) is characterized as ovarian cancer that comes back more than six months after platinum-based chemotherapy. While people with PSOC can often be treated with platinum again, the disease tends to return, and each recurrence can leave fewer treatment options and shorter remissions.5 What is the current unmet need in platinum-sensitive ovarian cancer (PSOC)? The standard of care for PSOC has remained largely unchanged for more than a decade, even as understanding of which patients benefit from it has evolved. Approximately 50% of PSOC patients have HRD-positive tumors, meaning their tumors carry a specific DNA-repair deficiency.6 These patients tend to have longer progression-free survival with upfront platinum-based chemotherapy plus a PARP inhibitor (PARPi).6 However, when these patients do recur after PARPi maintenance, response rates to subsequent platinum-based treatment are modest.6 Patients with non-HRD-positive tumors see minimal benefit from PARPi to begin with and generally have a poorer prognosis overall.6 Despite these different outcomes between HRD-positive and HRD-negative patients, treatment approaches for PSOC have not meaningfully changed to reflect that distinction. What is the difference between platinum-resistant (PROC) and platinum-sensitive ovarian cancer (PSOC)?The difference comes down to timing. If ovarian cancer returns more than six months after platinum-based chemotherapy, it's considered platinum-sensitive, and patients often respond well to platinum treatment again. If the cancer returns within six months, or continues growing during treatment, it's considered platinum-resistant, and platinum-based chemotherapy is generally no longer effective. Because platinum resistance tends to develop gradually, each recurrence can bring a shorter remission, even while a patient's disease is still classified as platinum-sensitive.6 What is folate receptor alpha (FRα), and why is FRα expression level important in treating ovarian cancer? FRα is expressed in almost all ovarian cancers, at much higher levels than in healthy tissue, making it a target that can help direct treatment to tumor cells.7 FRα expression level refers to the amount of the protein present on a tumor and may influence eligibility for or response to certain FRα-targeted therapies.7 How is the FRAmework-01 clinical trial designed? FRAmework-01 is a global, three-part Phase 3 trial studying sofetabart mipitecan (Sofe-M) across both platinum-resistant and platinum-sensitive ovarian cancer in a single program: Part A tests Sofe-M as monotherapy in platinum-resistant disease; Part B tests Sofe-M plus bevacizumab in platinum-sensitive disease that progressed on or within six months of completing a PARPi; and Part C tests Sofe-M plus bevacizumab in PARPi-naïve platinum-sensitive disease. The trial's main measure of success across all three parts is how long patients go without their cancer progressing. The study is being conducted in partnership with the European Network for Gynaecological Oncological Trial groups (ENGOT - lead groups GINECO/NOGGO e.V.), the GOG Foundation (GOG), and the Asia-Pacific Gynecologic Oncology Trials Group (APGOT). Enrollment is ongoing globally with first registrational dose in Q4 2025 for PROC and in Q1 2026 for PSOC.

About Ovarian Cancer

Ovarian cancer is the sixth leading cause of cancer death among women in the United States.8 While most patients initially respond to platinum-based chemotherapy, approximately 70% will experience recurrence, leading to progressively shorter remission periods with each subsequent treatment.6 When cancer recurs during or within six months of platinum therapy, known as platinum-resistant disease, patients face limited treatment options.6,9

About Sofetabart Mipitecan

Sofetabart mipitecan (Sofe-M; LY4170156) is composed of an Fc-silent, folate receptor alpha (FRα) specific humanized monoclonal antibody linked to exatecan, a topoisomerase I inhibitor, via a proprietary cleavable polysarcosine linker (PSARlink). Sofe-M was designed to target FRα across all expression levels with improved therapeutic index. FRα is a cell-surface glycoprotein encoded by the gene FOLR1 that binds to the essential nutrients folic acid and reduced folates, bringing them into cells to facilitate cell division and growth. FRα is overexpressed in many solid tumors such as ovarian and endometrial cancers. Sofe-M has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration for platinum-resistant ovarian cancer (PROC) and is currently being evaluated in the Phase 3 FRAmework-01 program. The study is being conducted in partnership with the European Network for Gynaecological Oncological Trial groups (ENGOT - lead groups GINECO/NOGGO e.V.), the GOG Foundation (GOG), and the Asia-Pacific Gynecologic Oncology Trials Group (APGOT).  

About FRAmework-01

FRAmework-01 (NCT07213804) is a Phase 3, randomized, open-label, three-part study evaluating sofetabart mipitecan (Sofe-M; LY4170156) in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. Part A tests Sofe-M as monotherapy in platinum-resistant disease; Part B tests Sofe-M plus bevacizumab in platinum-sensitive disease that progressed on or within six months of completing a PARPi; and Part C tests Sofe-M plus bevacizumab in PARPi-naïve platinum-sensitive disease. The primary endpoint is progression-free survival (PFS), assessed by the investigator in Part A and by blinded independent central review (BICR) in Parts B and C. Key secondary endpoints are overall survival, objective response rate, duration of response, and safety.  The FRAmework-01 study is in partnership with the European Network for Gynecological Oncological Trial groups (ENGOT - lead groups GINECO/NOGGO e.V.), the GOG Foundation (GOG), and the Asia-Pacific Gynecologic Oncology Trials Group (APGOT).

More information on FRAmework-01 can be found on clinicaltrials.gov.

References

Drago JZ, Modi S, Chandarlapaty S. Unlocking the potential of antibody-drug conjugates for cancer therapy. Nat Rev Clin Oncol. 2021;18(6):327-344. doi:10.1038/s41571-021-00470-8 2. Ray-Coquard, et al. Sofetabart mipitecan, an antibody drug conjugate targeting folate receptor alpha, in high grade ovarian cancer: Results from the first-in-human phase 1 study, Annals of Oncology (2026), doi: https://doi.org/10.1016/j.annonc.2026.10.001. Romeo M, Gil-Martín M, Gaba L, et al. Multicenter real-world data of subsequent chemotherapy after progression to PARP inhibitors in a maintenance relapse setting. Cancers (Basel). 2022;14(18):4414. Aghajanian C, Blank SV, Goff BA, et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol. 2012;30(17):2039-2045. Lesnock JL, Temin S, Bouberhan S, et al. Systemic Treatment of Ovarian Cancer Recurrence: ASCO Living Guideline, Version 2026.1.0. J Clin Oncol. Published online July 13, 2026. doi:10.1200/JCO-26-01591. Lheureux S, Braunstein M, Oza AM. Epithelial ovarian cancer: evolution of management in the era of precision medicine. CA Cancer J Clin. 2019;69(4):280-304. doi:10.3322/caac.21559. Bax HJ, Chauhan J, Stavraka C, et al. Folate receptor alpha in ovarian cancer tissue and patient serum is associated with disease burden and treatment outcomes. Br J Cancer. 2023;128(2):342-353. doi:10.1038/s41416-022-02031-x. American Cancer Society. Cancer Facts for Women. Accessed September 9, 2026. https://www.cancer.org/cancer/risk-prevention/understanding-cancer-risk/cancer-facts/cancer-facts-for-women.html. Colombo N, Sessa C, du Bois A, et al. ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease. Ann Oncol. 2019;30(5):672-705. doi: 10.1093/annonc/mdz062. About Lilly
Lilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit Lilly.com and Lilly.com/news, or follow us on Facebook, Instagram, and LinkedIn. P-LLY

© Lilly USA, LLC 2026. ALL RIGHTS RESERVED.

MSK Disclosure: Dr. Kyi has financial interests related to Eli Lilly and Company.             

Trademarks and Trade Names
All trademarks or trade names referred to in this press release are the property of the company, or, to the extent trademarks or trade names belonging to other companies are references in this press release, the property of their respective owners. Solely for convenience, the trademarks and trade names in this press release are referred to without the ® and ™ symbols, but such references should not be construed as any indicator that the company or, to the extent applicable, their respective owners will not assert, to the fullest extent under applicable law, the company's or their rights thereto. We do not intend the use or display of other companies' trademarks and trade names to imply a relationship with, or endorsement or sponsorship of us by, any other companies.

Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about sofetabart mipitecan plus bevacizumab and reflects Lilly's current beliefs and expectations. However, as with any pharmaceutical product, there are substantial risks and uncertainties in the process of drug research, development, and commercialization. Among other things, there is no guarantee that planned or ongoing studies will be completed as planned, that future study results will be consistent with study results to date, that any of these therapies will prove to be a safe and effective treatment or receive regulatory approval, or that Lilly will execute its strategy as expected. For further discussion of these and other risks and uncertainties that could cause actual results to differ from Lilly's expectations, see Lilly's Form 10-K and Form 10-Q filings with the United States Securities and Exchange Commission. Except as required by law, Lilly undertakes no duty to update forward-looking statements to reflect events after the date of this release.

SOURCE Eli Lilly and Company

The Chemours Company Securities Fraud Class Action Result of Overstatement of Refrigerant Aftermarket Demand and 18% Stock Decline - Investors may Contact Lewis Kahn, Esq., at Kahn Swick & Foti, LLCPR Newswire

NEW YORK and NEW ORLEANS, Oct. 23, 2026

, /PRNewswire/ -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with substantial losses that they have until December 7, 2026 to file lead plaintiff applications in a securities class action lawsuit against The Chemours Company ("Chemours" or the "Company") (NYSE: CC), if they purchased or otherwise acquired the Company's securities between February 20, 2026 and August 4, 2026, inclusive (the "Class Period"). This action is pending in the United States District Court for the District of Delaware.

What You May Do

If you purchased securities of Chemours as above and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, contact KSF Managing Partner Lewis Kahn toll-free at 1-833-538-3666 or via email ([email protected]), or visit https://www.ksfcounsel.com/cases/nyse-cc/ to learn more. If you wish to serve as a lead plaintiff in this class action, you must petition the Court by December 7, 2026.

>>>CLICK HERE for more information

About the Lawsuit

Chemours and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.

On August 4, 2026, post-market, the Company announced its 2Q 2026 financial results and cut its full-year adjusted EBITDA guidance to $775–$825 million, down from $800–$900 million. On the earnings call the next morning, CEO Denise Dignam admitted that "[a]s a result of the initial channel fill, aftermarket customers built additional inventory, creating an oversupplied channel heading into 2026." CFO Shane Hostetter added that, "from the Q2 and Q3 perspective, there's probably about $65 million of aftermarket sales that . . . probably should have been allocated to more of this year."

On this news, the price of Chemours' shares fell $3.34 per share, or 18.63%, to close at $14.59 per share on August 5, 2026.

The case is Darcy v. The Chemours Company, et al., No. 26-cv-01299.

>>>To Learn More, Click HERE

About Kahn Swick & Foti, LLC

KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation's premier boutique securities litigation law firms. This past year, KSF was ranked by SCAS among the top 10 firms nationally based upon total settlement value. KSF serves a variety of clients, including public and private institutional investors, and retail investors - in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, Delaware, California, Louisiana, Chicago, and a representative office in Luxembourg.

TOP 10 Plaintiff Law Firms - According to ISS Securities Class Action Services

To learn more about KSF, you may visit www.ksfcounsel.com.

>>>For More Information about the case, Click HERE

Contact:
Kahn Swick & Foti, LLC
Lewis Kahn, Managing Partner
[email protected]
1-833-538-3666
1100 Poydras St., Suite 960
New Orleans, LA 70163

CONNECT WITH US: Facebook || Instagram || YouTube || TikTok || LinkedIn

View original content to download multimedia:https://www.prnewswire.com/news-releases/the-chemours-company-securities-fraud-class-action-result-of-overstatement-of-refrigerant-aftermarket-demand-and-18-stock-decline---investors-may-contact-lewis-kahn-esq-at-kahn-swick--foti-llc-302918520.html

SOURCE Kahn Swick & Foti, LLC

-

Investigation follows the October 2, 2026 disclosure regarding Integra LifeSciences Holdings Corporation; investors who lost money may have claims to recover their losses

LOS ANGELES--(BUSINESS WIRE)--Investors who lost money on Integra LifeSciences Holdings Corporation ("Integra" or the "Company") stock may have claims to recover their losses. Glancy Prongay Wolke & Rotter LLP ("Glancy") today announced a securities fraud investigation on behalf of Integra LifeSciences Holdings Corporation (NASDAQ: IART) investors into whether the Company may have violated the federal securities laws. The investigation follows the October 2, 2026 disclosure regarding Integra LifeSciences Holdings Corporation.

Investors who lost money on Integra LifeSciences Holdings Corporation securities can submit their Integra LifeSciences Holdings Corporation loss information to learn about potentially pursuing claims to recover their losses.

Key facts in the Integra LifeSciences Holdings Corporation investigation

Disclosure date: October 2, 2026Stock price decline: $3.41 per share, or 21.2%Closing price after the decline: $12.68 on October 2, 2026What happened?

On October 2, 2026, Integra announced updated full year guidance and preliminary third quarter results. The Company disclosed, among other things, that due to a July flood at its Cincinnati manufacturing facility, “disruption negatively impacted third quarter revenue by approximately $7 million and is expected to negatively impact fourth quarter revenue by approximately $15 million to $20 million.” Integra also slashed its 2026 revenue guidance by approximately $30.5 million at the midpoint. 

On this news, Integra shares fell $3.41 or 21.2%, closing at $12.68 on October 2, 2026, thereby injuring investors.

Then, on October 21, 2026, Integra reported final third quarter results. Among other items, the Company disclosed “the Cincinnati disruption proved more significant than initially expected.” The Company announced it expected fourth quarter revenue of $413 million to $433 million (down 0.5% to 5.2%). The Company further disclosed “more measured expectations for portions of our Tissue Reconstruction business” in part because “growth in Tissue Reconstruction did not materialize as anticipated.”

On this news, Integra’s stock fell $1.49 or 11.18% to close at $11.84 on October 21, 2026, thereby injuring investors further.

"The price of Integra LifeSciences Holdings Corporation shares fell 21.2% following the October 2, 2026 disclosure that Integra had cut its 2026 revenue guidance by approximately $30.5 million at the midpoint and said a July flood at its Cincinnati manufacturing facility reduced third quarter revenue by about $7 million and would reduce fourth quarter revenue by $15 million to $20 million. Investors who suffered losses deserve to know whether they were given complete and accurate information prior to the disclosure, and our investigation seeks to answer that question," said Charles H. Linehan, Partner at Glancy Prongay Wolke & Rotter LLP.

What's the next step?

Glancy is investigating potential claims on behalf of Integra LifeSciences Holdings Corporation investors. Investors who lost money can contact Glancy about the Integra LifeSciences Holdings Corporation investigation, email [email protected], or call 310-201-9150 (toll-free: 888-773-9224).

Frequently Asked Questions

Who is eligible? Investors who bought Integra LifeSciences Holdings Corporation securities and lost money may have claims, and can contact Glancy to learn whether they are affected by the Integra LifeSciences Holdings Corporation investigation.

What is a securities fraud investigation? In the Integra LifeSciences Holdings Corporation investigation, Glancy is reviewing whether the Company or its executives may have made false or misleading statements to investors in violation of the federal securities laws.

Has a lawsuit been filed? This release announces Glancy's investigation, not a lawsuit. If a securities class action is later filed against Integra LifeSciences Holdings Corporation, investors may have the opportunity to seek appointment as lead plaintiff.

Does it cost anything to contact Glancy or participate in this investigation? Glancy represents Integra LifeSciences Holdings Corporation investors on a contingency fee basis, so investors pay no attorneys' fees out of pocket. Any attorneys' fees and litigation expenses are paid only from a recovery, if one is obtained, and are subject to court approval.

Why work with Glancy on the Integra LifeSciences Holdings Corporation investigation? Glancy Prongay Wolke & Rotter LLP is a premier law firm with decades of experience representing investors and consumers in securities litigation and other complex class action litigation. Contact Glancy about the Integra LifeSciences Holdings Corporation investigation. Prior results do not guarantee a similar outcome.

Whistleblower notice

Persons with non-public information about Integra LifeSciences Holdings Corporation should consider their options to aid the investigation or take advantage of the SEC Whistleblower Program. Under the program, whistleblowers who provide original information that leads to a successful SEC enforcement action may receive awards of 10 to 30 percent of the sanctions collected, when those sanctions exceed $1 million. For more information, contact Charles H. Linehan at 310-201-9150 or 888-773-9224, or email [email protected].

About Glancy Prongay Wolke & Rotter LLP

Glancy was named one of Law360's Securities Groups of the Year and ranked second in total investor recoveries by ISS Securities Class Action Services in 2025.

Glancy's successes have been widely covered by leading news and industry publications, including The Wall Street Journal, The Financial Times, Bloomberg Businessweek, Reuters, the Associated Press, Barron's, Investor's Business Daily, Forbes, and Money.

Prior results do not guarantee a similar outcome.

Related links

Integra LifeSciences Holdings Corporation investigation page, Glancy Prongay Wolke & Rotter LLPIntegra Q3 Financial ResultsIntegra LifeSciences Holdings Corporation SEC filings index, EDGARSEC Whistleblower ProgramGlancy Prongay Wolke & Rotter LLPThis press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

More News From Glancy Prongay Wolke & Rotter LLP

Back to Newsroom

Research Will Use Lunit's AI-powered Pathology Platform to Analyze H&E Whole-Slide Images and Generate Scalable Insights into Tumor Microenvironment Biology

, /PRNewswire/ -- Lunit Inc. (KRX: 328130) and Summit Therapeutics Inc. (NASDAQ: SMMT) today announced a research agreement to evaluate the use of Lunit SCOPE IO, Lunit's AI-powered pathology platform, for tumor microenvironment analysis in support of Summit's immuno-oncology development programs with ivonescimab.

Lunit and Summit Therapeutics The effort will focus on applying Lunit SCOPE IO to hematoxylin and eosin-stained (H&E) whole-slide images to characterize tumor microenvironment features. The companies aim to explore how AI-powered pathology analysis can support biomarker discovery, patient stratification or selection, and a deeper biological understanding of response to ivonescimab therapies.

Summit is developing ivonescimab, a novel, potential first-in-class investigational PD-1 / VEGF bispecific antibody, in several solid tumors. Lunit SCOPE IO is designed to support immuno-oncology research and biomarker development through AI-powered analysis of H&E slides, enabling scalable assessment of tumor microenvironment features without requiring additional stains or assays.

"Understanding the tumor microenvironment is increasingly important as immuno-oncology moves beyond single-axis checkpoint inhibition toward more complex mechanisms and combinations," said Allen Yang, MD, PhD, Chief Research and Development Strategy Officer of Summit. "We are pleased to work with Lunit to explore how AI-powered pathology can help generate deeper, more scalable insights from routine tissue samples and inform the continued development of ivonescimab."

"Summit is at the forefront of next-generation immuno-oncology development, and we are excited to support its efforts with Lunit SCOPE IO," said Brandon Suh, Lunit CEO. "By extracting quantitative, spatially resolved immune and tumor microenvironment features from standard H&E slides, we believe SCOPE IO can help biopharma partners better understand which patients may benefit from immuno-oncology therapies and why."

This agreement reflects the growing importance of computational pathology in oncology drug development. Routine H&E slides contain rich information about tumor architecture, immune infiltration, stromal organization, and spatial interactions within the tumor microenvironment. However, traditional manual assessment can be difficult to scale and may not fully capture the quantitative and spatial complexity of the tumor-immune interface. AI-powered analysis offers the potential to convert these routinely generated pathology images into reproducible, high-dimensional biomarker data.

The companies expect the work to generate tumor microenvironment insights that may inform future translational research, exploratory biomarker strategies, and clinical development planning. No clinical outcome data are being announced as part of this release.

 *Lunit SCOPE products are for research use only. Not for use in diagnostic procedures or decisions.

About Ivonescimab

Ivonescimab, known as SMT112 in Summit's license territories, North America, South America, Europe, the Middle East, Africa, and Japan, and as AK112 outside of Summit's license territories, is a novel, potential first-in-class investigational bispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects associated with blocking VEGF into a single molecule. By design, ivonescimab displays unique cooperative binding to each of its intended targets with multifold higher affinity to PD-1 when in the presence of VEGF.

This design is intended to differentiate ivonescimab as there is potentially higher expression (presence) of both PD-1 and VEGF in tumor tissue and the tumor microenvironment (TME) as compared to normal tissue in the body. Summit believes ivonescimab's specifically engineered tetravalent structure (four binding sites) enables higher avidity (accumulated strength of multiple binding interactions) in the TME (Zhong, et al, iScience, 2025). This tetravalent structure, the intentional novel design of the molecule, and bringing these two targets into a single bispecific antibody with cooperative binding qualities have the potential to direct ivonescimab to the tumor tissue versus healthy tissue. The intent of ivonescimab's design, together with a half-life of 6 to 7 days after the first dose (Zhong, et al, iScience, 2025) increasing to approximately 10 days at steady state dosing, is to improve upon previously established efficacy thresholds, side effects, and safety profiles associated with prior approved drugs to these targets.

Ivonescimab was invented by Akeso Inc. (HKEX Code: 9926.HK) and is currently utilized in multiple Phase III clinical trials. Over 5,000 patients have been treated with ivonescimab in clinical studies globally and over 100,000 patients when considering those treated in a commercial setting in China, as noted by Akeso.

There are currently 17 Phase III clinical studies that are either announced, ongoing, or have been completed studying ivonescimab, five of which are Summit-sponsored global studies, two of which are studies sponsored by cooperative groups, and 10 of which are being or have been conducted in China by Akeso. Summit began its clinical development of ivonescimab in NSCLC (HARMONi, HARMONi-3, HARMONi-7) and expanded its sponsored Phase III clinical development program into colorectal cancer (CRC; HARMONi-GI3) and urothelial carcinoma (bladder cancer; HARMONi-GU1). The two cooperative studies are in head and neck squamous cell carcinoma (HNSCC; ILLUMINE) and biliary tract cancer (BTC; EA2251).

Five Phase III ivonescimab clinical trials have read out to date, all five with positive data. Four of these five studies are in NSCLC and one is in BTC. In addition to Summit's positive HARMONi study in NSCLC, Akeso has had positive read-outs in four single-region (China), randomized Phase III clinical trials, HARMONi-A, HARMONi-2, HARMONi-6 (each in NSCLC), and HARMONi-GI1 (in BTC) for ivonescimab, including a statistically significant overall survival benefit in all four studies from China.

Akeso is actively conducting additional Phase III clinical studies in settings outside of NSCLC and biliary-tract cancer, including triple-negative breast cancer, head and neck squamous cell carcinoma, small cell lung cancer, colorectal cancer, and pancreatic cancer.

Ivonescimab is an investigational therapy that is not approved by any regulatory authority in Summit's license territories, including the United States and Europe. Ivonescimab was initially approved for marketing authorization in China in May 2024.

About Lunit

Founded in 2013, Lunit (KRX: 328130) is a global leader on a mission to conquer cancer through AI. Our clinically validated solutions span medical imaging, breast health, and biomarker analysis, empowering earlier detection, smarter treatment decisions, and more precise outcomes across the cancer care continuum.

Lunit offers a comprehensive suite spanning risk prediction and early detection to precision oncology. Our FDA-cleared Lunit INSIGHT Breast Suite and breast health solutions support cancer screening in thousands of medical institutions worldwide, while the Lunit SCOPE platform is used in research partnership with global pharma and laboratory leaders for biomarker research, and companion diagnostic development.

Trusted by over 10,000 sites in more than 65 countries, Lunit combines deep medical expertise with continuously evolving datasets to deliver measurable impact for patients, clinicians, and researchers alike. Headquartered in Seoul with global offices, Lunit is driving the worldwide fight against cancer. Learn more at lunit.io.

About Summit Therapeutics Inc.

Summit Therapeutics Inc. is a biopharmaceutical oncology company focused on the discovery, development, and commercialization of patient-, physician-, caregiver- and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs.

Summit was founded in 2003 and the company's shares are listed on the Nasdaq Global Market (symbol "SMMT"). Summit is headquartered in Miami, Florida, with additional offices in Palo Alto, California, Princeton, New Jersey, Dublin, Ireland, and Oxford, UK.

For more information, please visit https://www.smmttx.com and follow Summit on X @SMMT_TX.

Lunit Forward-Looking Statements

This press release contains forward-looking statements, including statements regarding the expected benefits of the collaboration, the potential use of AI-powered pathology in immuno-oncology development, and the potential application of tumor microenvironment analysis in biomarker research and clinical development. These statements are based on current expectations and involve risks and uncertainties that could cause actual results to differ materially. Neither company undertakes any obligation to update these forward-looking statements, except as required by law.

Summit Forward-Looking Statements

Any statements in this press release about the Company's future expectations, plans and prospects, including but not limited to, statements about dilution to existing stockholders and potential adverse effects on the market price of the Company's common stock, including from future sales by AstraZeneca, the Company's broad discretion over the use of proceeds, and the possibility that the proceeds will not be sufficient to fund operations as long as anticipated, AstraZeneca's ownership and contractual rights, including Third Party acquisition participation, and registration rights, and potential conflicts of interest, the completion of the Private Placement does not depend on the parties entering into a definitive collaboration agreement, the Company's reliance on AstraZeneca for the supply of AstraZeneca's products and other contributions to the clinical trials, the clinical and preclinical development of the Company's product candidates, entry into and actions related to the Company's partnership with Akeso Inc. and other collaborations, the intended use of the net proceeds from the private placements, the Company's anticipated spending and cash runway, the therapeutic potential of the Company's product candidates, the potential commercialization of the Company's product candidates, the timing of initiation, completion and availability of data from clinical trials, the potential submission of applications for marketing approvals, the expected timing of BLA submissions or FDA decisions, potential acquisitions, statements about the previously disclosed At-The-Market equity offering program ("ATM Program"), the expected proceeds and uses thereof, the Company's estimates regarding stock-based compensation, and other statements containing the words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "would," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including the Company's ability to sell shares of our common stock under the ATM Program, the conditions affecting the capital markets, general economic, industry, or political conditions, including the effects of geopolitical developments, domestic and foreign trade policies, and monetary policies, the results of our evaluation of the underlying data in connection with the development and commercialization activities for ivonescimab, the outcome of discussions with regulatory authorities, including the Food and Drug Administration, the uncertainties inherent in the initiation of future clinical trials, availability and timing of data from ongoing and future clinical trials, the results of such trials, and their success, global public health crises, that may affect timing and status of our clinical trials and operations, whether preliminary results from a clinical trial will be predictive of the final results of that trial or whether results of early clinical trials or preclinical studies will be indicative of the results of later clinical trials, whether business development opportunities to expand the Company's pipeline of drug candidates, including without limitation, through potential acquisitions of, and/or collaborations with, other entities occur, expectations for regulatory approvals, laws and regulations affecting government contracts and funding awards, availability of funding sufficient for the Company's foreseeable and unforeseeable operating expenses and capital expenditure requirements and other factors discussed in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of filings that the Company makes with the Securities and Exchange Commission. Summit defines a "positive study" as a clinical study with one or more prespecified primary endpoints in which one of those endpoints achieves a statistically significant benefit according to the protocol or statistical analysis plan. Any change to our ongoing trials could cause delays, affect our future expenses, and add uncertainty to our commercialization efforts, as well as to affect the likelihood of the successful completion of clinical development of ivonescimab. Accordingly, readers should not place undue reliance on forward-looking statements or information. In addition, any forward-looking statements included in this press release represent the Company's views only as of the date of this release and should not be relied upon as representing the Company's views as of any subsequent date. The Company specifically disclaims any obligation to update any forward-looking statements included in this press release.

SOURCE Lunit Inc.

Hyperliquid Strategies Inc. (NASDAQ: PURR) has increased its stock repurchase program from $30 million to $100 million, expanding its authorization as shares of the HYPE treasury company have declined more than 30% from their October high.

The company said Friday that approximately $72 million remains available under the expanded program, while its board extended the authorization’s expiration date from December 5, 2026, to October 31, 2027.

Hyperliquid Strategies said the increase reflects its board’s confidence in the company’s long term capital strategy and provides additional flexibility to repurchase shares as part of its treasury management operations.

Repurchases may be conducted through open market purchases, privately negotiated transactions or other methods permitted under federal securities laws.

The company said the timing and size of purchases will depend on market conditions, share prices and regulatory requirements. The authorization does not guarantee that the remaining funds will be used, and the program may be suspended or discontinued.

PURR shares and HYPE underperform Bitcoin in October
The announcement comes as Hyperliquid Strategies and HYPE, the native token of the Hyperliquid blockchain, have experienced steeper declines than Bitcoin this month.

PURR shares traded near $8.80 on Friday, down approximately 33% from an October 5 high of $13.05, according to Yahoo Finance data.

HYPE has also declined more than 18% from its October high near $95, trading around $77 despite Bitcoin remaining relatively stable over the same period.

Bitcoin, meanwhile, has traded largely between $80,000 and $87,000 during October, declining approximately 6% from its monthly high near $87,000.

The comparison highlights the relative weakness of HYPE and PURR, with the company’s shares recording a considerably larger decline than both the underlying token and Bitcoin.

Hyperliquid Strategies operates as a digital asset treasury company focused on accumulating HYPE and providing investors with exposure to the Hyperliquid ecosystem.

Its strategy involves generating returns through HYPE staking, yield optimization and active participation in the network, rather than relying exclusively on changes in the token’s market price.

The company describes itself as the largest digital asset treasury vehicle focused on HYPE, targeting US and institutional investors seeking exposure to the blockchain’s growth.

Disclosure: This article was edited by Estefano Gomez. For more information on how we create and review content, see our Editorial Policy.

For the quarter ended September 2026, Halliburton (HAL - Free Report) reported revenue of $5.7 billion, up 1.8% over the same period last year. EPS came in at $0.60, compared to $0.58 in the year-ago quarter.

The reported revenue represents a surprise of +1.98% over the Zacks Consensus Estimate of $5.59 billion. With the consensus EPS estimate being $0.58, the EPS surprise was +3.45%.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how Halliburton performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

Revenue- Latin America: $1.12 billion versus $1.06 billion estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +12.7% change.Revenue- Europe/Africa/CIS: $1.02 billion versus the three-analyst average estimate of $924.3 million. The reported number represents a year-over-year change of +22.7%.Revenue- North America: $2.16 billion versus the three-analyst average estimate of $2.29 billion. The reported number represents a year-over-year change of -8.6%.Revenue- Middle East/Asia: $1.41 billion versus $1.3 billion estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -0.5% change.Revenue- Drilling and Evaluation: $2.61 billion compared to the $2.41 billion average estimate based on five analysts. The reported number represents a change of +10% year over year.Revenue- Completion and Production: $3.09 billion compared to the $3.16 billion average estimate based on five analysts. The reported number represents a change of -4.2% year over year.Operating income- Completion and Production: $457 million versus the five-analyst average estimate of $515.8 million.Operating income- Drilling and Evaluation: $391 million compared to the $338.22 million average estimate based on five analysts.Operating income- Corporate and other: $-75 million versus $-102.5 million estimated by two analysts on average.View all Key Company Metrics for Halliburton here>>>

Shares of Halliburton have returned +1.3% over the past month versus the Zacks S&P 500 composite's -1.2% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

Large speculators in CME Bitcoin futures held a net long position of 2,418 contracts for the week of October 20, 2026, according to the Commodity Futures Trading Commission’s latest Commitments of Traders report.

That is a slight pullback from the prior week’s 2,534 contracts.

The report, released October 23, also showed speculators paring bets against most US Treasury futures. Meanwhile, the euro sat deep in net short territory.

What the Bitcoin numbers show
The CFTC publishes its Commitments of Traders, or COT, data every Friday at 3:30 p.m. ET. Each release reflects positions as of the preceding Tuesday.

The 2,418-contract figure covers non-commercial speculators in CME Bitcoin futures. It blends standard and micro contracts under the legacy reporting format.

A standard CME Bitcoin contract represents 5 BTC, while a micro contract represents just 0.1 BTC.

For context, the week ending October 13 showed large speculators net long 2,534 contracts, with total open interest of 20,752 contracts. Open interest measures the total number of outstanding contracts that have not been closed out.

The more granular Traders in Financial Futures breakdown told a split story for that October 13 week. Leveraged funds, a category that typically includes hedge funds, were net short roughly 5,844 standard contracts.

Asset managers and institutions, by contrast, were net long 3,642 contracts.

Treasuries, equities and the euro
The broader report showed a fairly consistent theme in the bond market: speculators trimming short positions.

Speculators cut their net short in CBOT US 2-year Treasury futures by 54,796 contracts to 856,783.
Net shorts in 5-year Treasury futures fell by 6,095 contracts to 1,074,109.
Net shorts in 10-year Treasury futures dropped by 23,809 contracts to 964,293.
Net shorts in CBOT US Treasury bond futures shrank by 58,019 contracts to 68,419.

The lone exception was the long end. Speculators increased their net short in UltraBond Treasury futures by 53,564 contracts to 375,161.

Equity fund speculators trimmed their S&P 500 CME net short by 42,221 contracts to 348,674.

Equity fund managers cut their S&P 500 CME net long by 18,079 contracts to 894,464.

In currencies, the euro held a net short position of 134,524 contracts.

Why the positioning matters
The COT report has an important limitation. It tells you what traders hold, not why they hold it, and it makes no attempt to forecast prices.

A net long can reflect outright bullish conviction. It can also be one leg of a hedged trade, such as a basis trade where a fund buys spot exposure and sells futures to capture the price gap between them.

That caveat is especially relevant to the Bitcoin data. The October 13 split, with leveraged funds net short and asset managers net long, is consistent with a market where some participants are hedging rather than simply calling direction.

The next COT report is anticipated on October 30, 2026. Traders watching Bitcoin will want to see whether open interest holds near the 20,752-contract level recorded for October 13, and whether speculators keep inching back from their net long or start adding again.

Disclosure: This article was edited by Vivian Nguyen. For more information on how we create and review content, see our Editorial Policy.

Ripple Labs has formally endorsed the US Securities and Exchange Commission’s proposed Regulation Crypto Assets, calling for its swift adoption as a binding rule. The company submitted its comment letter on October 20, 2026, coinciding with the final day for public input on the agency’s releases 33-11434 and 34-106150 (File No. S7-2026-27).

Ripple’s position on crypto regulationChief Legal Officer Stuart Alderoty, General Counsel Sameer Dhond, and Deputy General Counsel Deborah McCrimmon signed Ripple’s letter. The document states that Ripple “fully supports the Commission’s efforts to provide a regulatory framework for crypto assets, and urges the Commission to adopt the Proposal in a final rule.”

Ripple emphasized that a regulatory framework rooted in existing US securities law could offer much-needed clarity to the crypto industry, reducing the need for piecemeal enforcement actions and fostering domestic innovation.

Ripple, a blockchain technology company known for its digital payment protocol and the digital asset XRP, pointed out that the SEC’s proposal builds on a joint interpretation of existing securities laws by both the SEC and the Commodity Futures Trading Commission (CFTC). This interpretation relies on the Howey investment-contract test as a legal basis for crypto asset oversight.

The firm argued that the presence of an investment contract does not automatically render the underlying token a security. Instead, Ripple contended, the legal status should hinge on the issuer’s promises and representations throughout the contract’s life—rather than applying a permanent securities designation to the token or using a decentralization test as the sole criterion.

Ripple also incorporated its previous correspondence with the SEC’s Crypto Task Force in 2025 and 2026, providing additional context for its views.

Industry impact and legal contextStuart Alderoty has previously commented that the company spent over $150 million on legal efforts to resolve its longstanding dispute with the SEC over XRP’s regulatory status.

According to Ripple, the proposed regulation could replace the uncertainty of case-by-case enforcement with clearer, predictable rules. The company maintains that this approach would encourage capital formation in the US and reduce the likelihood of crypto innovators seeking opportunities overseas.

While expressing general support, Ripple advocated for targeted improvements. One specific request involved clarifying that Form TR filings should not be treated as an admission of previous securities status or legal violations.

The official comment window for the SEC’s proposal closed on October 20. However, the Commission confirmed that it will continue to accept public feedback as it considers whether to finalize the framework. Ripple’s endorsement arrives as a significant statement from a leading US blockchain firm as policymakers deliberate over the future of crypto regulation.

Mini dictionary: Howey test – A legal test established by the US Supreme Court to determine whether certain transactions qualify as investment contracts and therefore fall under the definition of a security, based on whether there is an investment of money in a common enterprise with an expectation of profits from the efforts of others.

AspectCase-by-case enforcementProposed SEC FrameworkClarityUnpredictableClearer regulatory pathImpact on innovationEncourages offshore movesSupports domestic capital formationLegal foundationAd hoc litigationGrounded in existing lawWith the SEC’s comment period concluded, industry attention now shifts to how the agency will address feedback from market participants. Ripple’s recommendations and support may influence the final form of US crypto regulations as authorities evaluate the balance between investor protection and industry growth.

The company’s public stance underscores the high stakes for both market participants and regulators as new federal rules for digital assets move closer to completion.

Spot ether ETFs have lost $1.2 billion in October and Bitmine is weeks from its 5% cap, leaving ETF flows to decide who absorbs ether’s new supply into year-end.

Ether's spot ETF buyers and its largest corporate holder are both pulling back in October.

Posted October 23, 2026 at 3:00 pm ET.

Ether’s (ETH) demand this year has largely come from two places: spot exchange-traded funds (ETFs) and Bitmine Immersion Technologies (BMNR), the company building an ether treasury. In October, both are pulling back at once.

No month this year has seen spot ether ETFs lose as much as October, with $1.2 billion in net outflows so far. Investors pulled money on all but two trading days through Oct. 22.

Bitmine, meanwhile, is about 66,000 ETH short of its goal of owning 5% of all ether, by our count from its latest holdings update. At the company’s current pace, it hits its target late next month.

Ether bulls often parse their outlooks through adoption headlines, like JPMorgan bringing its deposit token to Ethereum this week. Adoption builds the network, but it only lifts the price when someone buys the coin. Presently, the question is who absorbs the roughly 20,000 new ETH the network issues every week once Bitmine stops.

This issue of Bits + Bips measures how much of that supply Bitmine has been taking, why no other ether treasury can take over, and what ETF flows would need to look like for ether to hold up into year-end.

Spot ether ETFs swung from $2.7 billion of net inflows in August and September to $1.2 billion of net outflows in October through Oct. 22. Source: SoSoValue; Farside. Bitmine’s Buying Has Already Slowed Bitmine is finishing its accumulation at a fraction of the pace it started with. The company has bought ether every week since June 30, 2025. In April and May it bought more than 100,000 ETH in a single week four times. In each of the last two weeks it bought about 12,500.

It now holds 6.04 million ETH, or 4.9% of Ethereum‘s circulating token supply, and its cash has fallen by about $30 million a week with no new capital raise in its last three updates.

“We’re done stacking,” Bitmine Chair Tom Lee said earlier this month in a message to investors.

Bitmine’s 5% ether target is “a hard cap,” Lee said at the Token2049 conference, adding, “We’re not gonna be accumulating past 5%.”

One caveat on timing: 5% of ether’s supply is a moving target. Supply grows by about 87,000 ETH a month, so the finish line moves out by roughly 4,300 ETH a month, by our count.

Additionally, Ethereum’s issuance is subject to change, and not fixed at roughly 20,000 new ETH per week. The network uses a fee-burning mechanism that dynamically adjusts to user demand. At times of high use, like in 2023, this mechanism burns more tokens than are created to pay the validators that secure the network, actually turning Ethereum’s token economy deflationary. That said, ether token inflation has stayed relatively stable this year, in part due to a migration of user activity onto Layer-2 networks, which has left mainnet gas fees too low to burn off the newly issued coins.

ETF Money Moves in Billions The ETFs have been the larger and less predictable buyer this year. Net inflows reached $1.85 billion in August and another $832 million in September, then reversed in October.

The funds now hold roughly 6.2 million ETH, about the same as Bitmine, from their combined net assets of $14.6 billion. However, the two buyers move at very different speeds. October’s outflows have averaged about $357 million a week. Bitmine’s recent purchases come to about $30 million a week at its own reported prices. The ETF swing is about 12 times larger.

In the rest of the issue, subscribers get:

How much of ether’s new supply Bitmine has been absorbing, and why part of the hand-off has already happened Why no other ether treasury can step in, judged by what their shares trade at against their coins What is driving October’s ETF outflows The weekly ETF number that would cover ether’s new supply after Bitmine stops, plus bull, base and bear ranges for ETH into year-end Already a subscriber? Keep reading.

Why serious investors subscribe:

Clear thinking during macro regime changes

Fewer trades, better decisions

Avoiding one bad allocation often matters more than finding one great trade

An early Ethereum investor has moved 3,000 ETH, valued at approximately $7.23 million, to crypto exchange Kraken. According to onchain data tracked by analytics platform Lookonchain, the transfer took place on Friday. The wallet in question acquired the ETH about nine years ago at an average price of $18.83 per token, booking an estimated 128-fold profit on the original purchase price.

Major profit for early Ethereum adopterOnchain monitoring revealed that the investor’s wallet, identified as 0xa4c2CA8d5A6f488604cA417C0aaCe8E2621F02D0 and tagged by crypto intelligence firm Arkham Intelligence, received the initial ETH funds from a Gemini hot wallet and an additional address between 2015 and 2016.

Lookonchain reported that the 3,000 ETH transfer to Kraken signals the possible liquidation of the holdings. While deposits to exchanges often precede sales, there is no public order data confirming that the entire stack was sold in a single transaction or at one price. Nonetheless, assuming a current ETH price near $2,410, the investor’s $56,500 original cost would have appreciated to over $7.2 million.

The 3,000 ETH transferred to Kraken can be traced back to purchases made nine years ago, representing a significant return on investment for the early adopter based on today’s ETH price.

Mini dictionary: Arkham Intelligence is a blockchain analytics company specializing in tracking and labeling crypto wallets to provide transparency and risk assessment for market participants.

Ethereum price steadies despite large holder’s exitDespite the sizable transfer, ETH’s market price held steady. CoinMarketCap data showed Ethereum trading at $2,405.81, up 1.27% in the last 24 hours. Analysts noted that recent gains have been supported by modest capital rotation into alternative cryptocurrencies, while Bitcoin’s market dominance eased during the same period.

No direct evidence suggests that the early investor’s transfer affected market prices. Ethereum continued to trade in a narrow range through the session, with the broader crypto market displaying similar stability. The current movement is seen as part of ongoing price consolidation, rather than a response to isolated large holder actions.

Ethereum demonstrates resilience as it remains within a consolidation range, even after a major early adopter moved 3,000 ETH to an exchange for potential sale.

Support and resistance levels draw trader focusMarket observers are closely watching key technical levels for Ethereum. According to analyst CryptoBusy, ETH is testing an ascending trendline with support between $2,350 and $2,480, following a recent decline from $2,700. If buyers maintain the $2,350 level, a recovery toward $2,500 is projected, with $2,800 identified as the next major resistance point.

On the downside, a decisive break below $2,350 could prompt further losses toward $2,200. CoinMarketCap notes a similar outlook, suggesting a support band at $2,350–$2,390. Across several analyst assessments, $2,350 has emerged as a critical line to monitor. These technical perspectives will likely shape near-term trading strategies.

Key LevelScenarioAction Point$2,350SupportBreak below signals possible drop to $2,200$2,480Support/ResistanceDefend for bounce toward $2,500/$2,800$2,800Major resistanceBreak above signals next upside targetMacro events may influence upcoming moves. CoinMarketCap identified the upcoming Federal Reserve policy meeting on October 27-28 as a relevant potential catalyst. Trader Daan Crypto Trades emphasized the importance of waiting for a clear resolution above or below this range before making directional bets, citing continued price congestion between $2,350 and $2,550.

While the early investor’s transfer drew attention, analysts suggest Ethereum’s immediate trajectory will depend on the defense or loss of key technical support, with broader macro triggers such as central bank policy potentially steering market direction in the coming days.

Gentex lowered its 2026 revenue guidance to approximately $2.65 billion, down from a prior range of $2.65 billion to $2.75 billion. Shareholders holding losses may have rights worth reviewing now.

, /PRNewswire/ -- The high end of Gentex Corporation's (NASDAQ: GNTX) 2026 revenue outlook dropped to its previous floor alongside third-quarter results on October 23, 2026, and GNTX shares fell to open at just $20.21, an overnight decline of more than 7%. If you bought Gentex stock and are now looking at a loss, you have rights as a shareholder. Investors who lost money on GNTX are encouraged to find out what rights they have as Gentex shareholders . You may also contact Joseph E. Levi, Esq. via email at [email protected]  or by telephone at (212) 363-7500.

Before the third-quarter report, Gentex guided for 2026 revenue of $2.65 billion to $2.75 billion. The updated guidance is approximately $2.65 billion. That figure is the low end of the prior range and $50 million below its $2.70 billion midpoint. Third-quarter sales came in at $647.7 million, down from $655.2 million a year earlier. The Company's gross margin outlook decline as well, from a 35% midpoint to about 34.25%.

Levi & Korsinsky is investigating on behalf of Gentex shareholders to evaluate whether potential securities law claims exist. Shareholders who suffered losses may be able to seek recovery whether they still hold GNTX or have already sold. A review of your losses costs nothing and carries no obligation.

Gentex shareholders with losses can have their GNTX losses evaluated today  or call Joseph E. Levi, Esq. at (212) 363-7500.

Levi & Korsinsky, LLP  | Top 50 Securities Firm | (212) 363-7500 | www.zlk.com
Frequently Asked Questions About the GNTX Investigation
Q: Who is conducting the GNTX investigation?  A: Levi & Korsinsky, LLP is investigating potential securities law claims on behalf of investors who purchased GNTX securities. The firm is nationally recognized, ranked in the ISS Top 50 for seven consecutive years, and has recovered hundreds of millions of dollars for aggrieved investors.

Q: Who is eligible to participate in the GNTX investigation?  A: Investors who purchased GNTX stock or securities and suffered financial losses may be eligible. Eligibility is based on purchase date and documented losses -- not on whether you still hold the shares.

Q: What do GNTX investors need to do right now?  A: Investors may gather brokerage records showing purchase dates, share quantities, and prices paid. Submit your information for a no-cost, no-obligation evaluation of your potential recovery . No immediate action is required to remain eligible to participate in the investigation.

Q: What documents do I need to participate?  A: Brokerage statements or trade confirmations showing purchase dates, share quantities, prices paid, and any subsequent sale dates and prices.

Q: What if I already sold my GNTX shares -- can I still recover losses?  A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought GNTX and sold at a loss may still participate in the investigation.

Q: What if my GNTX losses are small -- is it still worth contacting a lawyer?  A: Yes. There is no minimum loss amount required to participate in the investigation.

Q: What does it cost me to participate?  A: There is no upfront cost to submit your information and review whether you may be eligible to recover. Should you choose to participate in any resulting action, these matters are generally handled on a contingency basis, with any attorneys' fees and expenses subject to court approval.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171

Attorney Advertising. Prior results do not guarantee similar outcomes.

SOURCE Levi & Korsinsky, LLP

VICI Properties Inc. (VICI - Free Report) ended the recent trading session at $23.76, demonstrating a -1.08% change from the preceding day's closing price. This change lagged the S&P 500's daily loss of 0.52%. Elsewhere, the Dow saw a downswing of 1.24%, while the tech-heavy Nasdaq depreciated by 0.21%.

Heading into today, shares of the company had gained 3.22% over the past month, outpacing the Finance sector's loss of 0.78% and the S&P 500's loss of 1.21%.

Investors will be eagerly watching for the performance of VICI Properties Inc. in its upcoming earnings disclosure. The company's earnings report is set to be unveiled on October 28, 2026. It is anticipated that the company will report an EPS of $0.62, marking a 3.33% rise compared to the same quarter of the previous year. Meanwhile, our latest consensus estimate is calling for revenue of $1.06 billion, up 5.67% from the prior-year quarter.

For the full year, the Zacks Consensus Estimates project earnings of $2.47 per share and a revenue of $4.22 billion, demonstrating changes of +3.78% and +5.26%, respectively, from the preceding year.

Investors should also note any recent changes to analyst estimates for VICI Properties Inc. Recent revisions tend to reflect the latest near-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.

Based on our research, we believe these estimate revisions are directly related to near-term stock moves. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.

Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate has remained steady. VICI Properties Inc. is currently sporting a Zacks Rank of #2 (Buy).

Looking at valuation, VICI Properties Inc. is presently trading at a Forward P/E ratio of 9.73. For comparison, its industry has an average Forward P/E of 11.85, which means VICI Properties Inc. is trading at a discount to the group.

The REIT and Equity Trust - Other industry is part of the Finance sector. With its current Zacks Industry Rank of 95, this industry ranks in the top 39% of all industries, numbering over 250.

The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.

SLM shares fell after the student lender disclosed it had paused most of its third-party recovery activities as third-quarter net charge-offs reached $90.4 million. Levi & Korsinsky is investigating potential securities law violations on behalf of SLM investors.

, /PRNewswire/ -- SLM Corporation (NASDAQ: SLM) shareholders are taking losses after the student lender disclosed on October 22, 2026 that it had paused the majority of its third-party recovery activities while third-quarter net charge-offs climbed to $90.4 million. If you bought SLM shares and lost money on this news, you may have legal rights. Investors who suffered losses are encouraged to submit your SLM loss details now . You may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500.

The disclosure appeared in SLM's Form 10-Q, filed after-market October 22, 2026, which indicated the Company was "pausing the majority of third-party recovery activities while we continue to develop and implement a more effective, customer-aligned approach." Net charge-offs for the first nine months of 2026 reached $292 million, up from $248 million in 2025.

Alongside a reduction of its annual guidance projection by more than a third, SLM increased their net charge-off guidance for the full year by $35 million to a range of $400 million to $420 million. Levi & Korsinsky is investigating whether SLM may not have adequately disclosed how changes to its collection and recovery practices could affect credit losses.

Shareholders who lost money on SLM can request a review of their SLM losses or call (212) 363-7500.

WHY LEVI & KORSINSKY -- Ranked in ISS Securities Class Action Services' Top 50 Report for seven consecutive years, Levi & Korsinsky, LLP is a nationally recognized leader in shareholder rights litigation. With a team of over 70 professionals, the firm has recovered hundreds of millions of dollars for investors.

Frequently Asked Questions About the SLM Investigation

Q: Who is eligible to participate in the SLM investigation? A: Investors who purchased SLM stock or securities and suffered financial losses may be eligible. Eligibility is based on purchase date and documented losses -- not on whether you still hold the shares.

Q: How much did SLM stock drop? A: From a closing price of $21.76 on October 22, 2026, SLM shares declined an initial $0.95, or 4.4%, when the market opened on October 23, 2026. By midday, the stock had fallen nearly than $2, or more than 9%, from the previous day's closing price. Investors who purchased shares at allegedly inflated prices and suffered losses may be eligible to seek compensation.

Q: What do SLM investors need to do right now? A: Investors may gather brokerage records showing purchase dates, share quantities, and prices paid. Submit your information for a no-cost, no-obligation evaluation of your potential recovery . No immediate action is required to remain eligible to participate in the investigation.

 Q: What documents do I need to participate? A: Brokerage statements or trade confirmations showing purchase dates, share quantities, prices paid, and any subsequent sale dates and prices.

Q: What if I already sold my SLM shares -- can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought SLM and sold at a loss may still participate in the investigation.

 Q: Do I need to go to court or give testimony? A: No. Participating in the investigation does not require court appearances or depositions. If legal action is later pursued, the overwhelming majority of affected investors never appear in court either.

 Q: What does it cost me to participate? A: There is no upfront cost to submit your information and review whether you may be eligible to recover. Should you choose to participate in any resulting action, these matters are generally handled on a contingency basis, with any attorneys' fees and expenses subject to court approval.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171

Attorney Advertising. Prior results do not guarantee similar outcomes.

SOURCE Levi & Korsinsky, LLP

For the quarter ended September 2026, Kinder Morgan (KMI - Free Report) reported revenue of $4.53 billion, up 9.3% over the same period last year. EPS came in at $0.35, compared to $0.29 in the year-ago quarter.

The reported revenue represents a surprise of +3.52% over the Zacks Consensus Estimate of $4.38 billion. With the consensus EPS estimate being $0.33, the EPS surprise was +6.06%.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how Kinder Morgan performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

Realized weighted average oil price: $/68.65 versus the two-analyst average estimate of $/71.4.Realized weighted average NGL price: $/34.48 versus $/35.06 estimated by two analysts on average.Terminals - Liquids leasable capacity: 78.70 MMBBL versus the two-analyst average estimate of 78.60 MMBBL.NGL sales volumes - net: 9.88 millions of barrels of oil compared to the 9.8 millions of barrels of oil average estimate based on two analysts.CO2 sales volumes - net: 0.27 Bcf/D compared to the 0.30 Bcf/D average estimate based on two analysts.Total oil production - net: 27.07 millions of barrels of oil versus 28.2 millions of barrels of oil estimated by two analysts on average.Terminals - Bulk transload tonnage: 13.50 MMTon versus 12.65 MMTon estimated by two analysts on average.Segment EBDA- Natural gas Pipelines: $1.5 billion versus $1.41 billion estimated by three analysts on average.Segment EBDA- Terminals: $385 million compared to the $284.75 million average estimate based on three analysts.Segment EBDA- Products Pipelines: $172 million compared to the $290.54 million average estimate based on three analysts.Segment EBDA- CO2: $172 million versus the three-analyst average estimate of $195.07 million.View all Key Company Metrics for Kinder Morgan here>>>

Shares of Kinder Morgan have returned +7.9% over the past month versus the Zacks S&P 500 composite's -1.2% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

In the latest close session, CRH (CRH - Free Report) was down 1.78% at $84.89. This change lagged the S&P 500's 0.52% loss on the day. Elsewhere, the Dow saw a downswing of 1.24%, while the tech-heavy Nasdaq depreciated by 0.21%.

Coming into today, shares of the building material company had gained 2.94% in the past month. In that same time, the Construction sector lost 6.53%, while the S&P 500 lost 1.21%.

The investment community will be paying close attention to the earnings performance of CRH in its upcoming release. The company is slated to reveal its earnings on October 29, 2026. The company's earnings per share (EPS) are projected to be $2.14, reflecting a 3.17% decrease from the same quarter last year. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $11.72 billion, up 5.87% from the year-ago period.

For the full year, the Zacks Consensus Estimates project earnings of $5.83 per share and a revenue of $39.6 billion, demonstrating changes of +4.67% and +5.75%, respectively, from the preceding year.

Investors might also notice recent changes to analyst estimates for CRH. These recent revisions tend to reflect the evolving nature of short-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.

Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.

The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 1.24% downward. As of now, CRH holds a Zacks Rank of #3 (Hold).

Looking at valuation, CRH is presently trading at a Forward P/E ratio of 14.83. This expresses a discount compared to the average Forward P/E of 17.08 of its industry.

Also, we should mention that CRH has a PEG ratio of 1.57. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company's anticipated earnings growth rate. Building Products - Miscellaneous stocks are, on average, holding a PEG ratio of 1.5 based on yesterday's closing prices.

The Building Products - Miscellaneous industry is part of the Construction sector. This industry currently has a Zacks Industry Rank of 204, which puts it in the bottom 18% of all 250+ industries.

The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.

Canary Capital’s exchange-traded fund (ETF), which tracks Hedera (HBAR), has continued its listing on NASDAQ with steady trading activity through a challenging year for the digital asset. Despite HBAR losing 52% of its value over the past twelve months and falling 28% year-to-date, the ETF posted a notable 69% cumulative increase in net inflows for the same period.

Institutional Resilience Amid Market DeclineThis persistent influx signals strong institutional commitment, even as market sentiment around HBAR remains weak. The ETF’s asset base reached $113 million, reflecting consistent demand. However, net flows have recently stagnated, with three consecutive weeks without any new inflows in the last quarter.

Last week saw net outflows of $558,980, attributed to larger investors reducing their positions amid geopolitical uncertainty. This withdrawal follows a period when the ETF was attracting several hundred thousand dollars per week, suggesting that while institutional participants are not broadly exiting, some have scaled back their exposure.

This slow but steady shift points to large investors methodically adjusting allocations in response to prolonged bearish trends, rather than abandoning their positions entirely.

A segment of institutional participants is treating current HBAR price levels as an opportunity, guided by indicators like the Market Value to Realized Value (MVRV) index. When this metric turns negative, it signals the chance to purchase at what could be considered discounted prices, as earlier investors may have absorbed much of the earlier sell-off.

Mini dictionary: MVRV index — The Market Value to Realized Value (MVRV) index measures the ratio between a cryptocurrency’s total market cap and its realized cap. A negative MVRV can indicate that the asset is potentially undervalued, often prompting accumulation by long-term investors.

HBAR Trading Activity and On-Chain DataHedera’s spot trading volume reached $154,901,395 over 24 hours, while derivatives activity was slightly higher at about $180 million for the same period. According to analytics provider SoSoValue, HBAR’s spot market turnover rate stands at 4.45% in that window. Although the long versus short ratio is currently marginally in favor of bullish traders at 1.069, the liquidation data paints a different picture.

Out of $430,500 in liquidated HBAR positions, $422,600 were from long positions, highlighting that short-sellers have recently gained momentum. They appear to be testing support near the $0.08 mark, with HBAR currently trading at $0.079. This price sits below the key SuperTrend resistance value of $0.096 and the $0.086 mid-range Bollinger Band.

MetricValueHBAR price (current)$0.079SuperTrend level$0.096Bollinger Band (mid)$0.086Spot trading volume (24h)$154,901,395Derivatives volume (24h)$180,000,000Long vs Short Ratio1.069Long liquidations (24h)$422,600Total liquidations (24h)$430,500ETF net inflow (12 months)+69%ETF asset value$113 millionHBAR yearly change-52%HBAR YTD change-28%Recovery to higher price levels could depend on renewed whale participation and further institutional buying. The lack of substantial inflows in recent weeks suggests that while conviction in the ETF remains, cautious positioning prevails.

A positive shift in trading activity and whale accumulation may be required if HBAR is to reclaim significant resistance points above $0.08 in the near term.

TLDR: Santiment counted 2,295 new UNI addresses in one day, the highest network-growth reading since November 2022, based on first-time interactions with UNI. Santiment pointed to new Uniswap v4 features, expanded liquidity routing and continued Unichain development as possible reasons for the increase, without naming a single driver. Santiment identified $7 as the key downside level, $7.50 as the first meaningful reclaim and $8 as a possible retest if support and network activity remain firm. If UNI loses $7 while new address creation fades, Santiment said the spike may reflect short-term excitement rather than sustained adoption; follow-through will clarify the trend. UNI wallet creation reached 2,295 addresses in one day, its highest network growth reading since November 2022, Santiment said. The increase puts network activity near levels last seen four years ago, while UNI remains close to $7. Santiment linked the rise in participation to three factors: 

Uniswap v4 features, liquidity routing and continued work on Unichain. The metric tracks new addresses that interact with UNI for the first time. It does not show how many people control those addresses or whether each will remain active. For traders, the wallet surge adds an adoption signal to the price levels in focus.

UNI Wallet Creation Reaches a Four-Year Network Growth Peak The UNI wallet creation count marks the strongest daily increase since November 2022. Santiment defines network growth by counting addresses that interact with UNI for the first time. The figure measures fresh on-chain participation, not a direct count of new customers. One person may control several wallets, while some addresses may see little activity after their first interaction. The data shows a jump in first-time address activity, but cannot confirm lasting adoption by itself.

Source: Santiment Santiment pointed to Uniswap v4 features, expanded liquidity routing and ongoing Unichain development as possible reasons for the increase. Together, these developments give users new ways to access the protocol and ecosystem. The post did not say which development contributed most, however. Nor does the one-day reading show that each new address arrived because of a specific product. The explanations remain plausible, while the increase in first-time addresses is the measured signal.

The next test is whether UNI wallet creation stays elevated. Santiment said readings above the recent baseline could strengthen the case for continued participation. If counts quickly fall back, the daily high may reflect short-term attention. Several days of elevated activity would offer stronger evidence that new addresses keep exploring UNI. Daily growth can fluctuate, so traders may seek follow-through before treating it as a lasting change.

UNI Price Levels Put $7 Support and $7.50 Reclaim in Focus UNI’s price structure centers on $7.00 and $7.50. Santiment called $7 the key downside level and $7.50 the first meaningful reclaim. These levels frame the immediate question: can buyers defend support, then recover initial resistance? Wallet growth adds context, but neither the network metric nor these levels guarantees a move. Confirmation depends on price response and continued activity.

If UNI holds above $7 while new address growth stays above its recent baseline, Santiment said a renewed test of $8 would be favored. That scenario pairs price stability with continuing participation. A reclaim of $7.50 is the first level to watch before any move toward $8. A push through $7.50 would show buyers recovering ground, but one brief move would not establish a breakout. Follow-through in both price and UNI wallet creation would strengthen the recovery case.

Source: TradingView If UNI falls below $7 as UNI wallet creation fades, Santiment said the spike could reflect short-term excitement rather than sustained adoption. If price slips under support while activity remains strong, the signals conflict. If activity fades but price holds, traders still need evidence that buyers will defend $7. Daily closes and new address counts may clarify which pattern is developing.

The two indicators answer different questions. Wallet counts show whether new addresses are beginning to interact with UNI, while price shows whether buyers are absorbing available supply. A rise in new addresses can coincide with a flat or falling token price when selling demand is stronger. 

Securitize has confirmed that 12 tokenized U.S. stocks, including Apple, Nvidia and Tesla, are live on Solana for eligible investors, with each token backed by a share the company says is never lent out.

Summary

12 stock tokens are live on Solana, including Apple, Nvidia, Tesla, Microsoft, and Amazon.
Securitize says backing shares are never lent out, and eligible U.S. investors can participate.
Holders receive security entitlements; direct registration requires conversion, subject to the available arrangements.
The original launch announcement dates to Oct. 8, before the latest posts confirming availability.

In its Oct. 23 X post, Securitize said that eligible investors in the United States, European Union and other permitted jurisdictions can trade the products through Securitize Stocks. Solana repeated the availability announcement, including the one-for-one backing and no-lending claims.

Securitize Stocks went live after an Oct. 8 announcement
Securitize’s original announcement named Apple, Microsoft, Nvidia, Alphabet, Tesla, Meta, Amazon, Netflix, Circle, SpaceX, Strategy, and Palantir in the initial offering. The latest promotional image displays the same companies, including Alphabet’s GOOGL ticker.

The company had announced the product on Oct. 8. Its Oct. 23 posts describe the stocks as available, without announcing a new set of 12 companies or a separate expansion in the number of products.

As crypto.news previously reported on Oct. 9, the stock entitlement structure gives holders an interest through an intermediary. Simply holding a token does not put the investor’s name on the underlying company’s shareholder register.

The earlier coverage identified eligibility and the precise underlying interest as questions for individual products, particularly SpaceX. Inclusion in a platform’s catalog does not by itself establish identical access conditions for every security or investor.

The Oct. 8 release named Jump Trading as a market maker supporting the initial Solana offering. It described transactions settling in USDC and identified Securitize Europe Brokerage and Markets, S.A. as the offering entity in the EU. Planned lending and collateral uses were described as future applications, including potential support through Aave.

Eligible US investors must complete onboarding
Securitize’s product page identifies Securitize Markets, LLC as the SEC-registered broker-dealer offering the stocks. The page says participation remains subject to onboarding, identity verification, and jurisdictional eligibility.

Investors can buy with USDC and hold the tokens in an approved Solana wallet, according to the product description. The page advertises trading 24 hours a day, five days a week, while describing seven-day trading as a future feature.

The platform says an underlying share is held in a segregated account for each tokenized stock. Its description includes dividend payments after applicable withholding and participation in shareholder votes.

Securitize’s disclosures state that the underlying issuers have neither sponsored nor endorsed the products. Investors hold security entitlements through the broker-dealer and become registered shareholders only if they convert.

The page warns that extended-hours trading carries additional risks. Its USDC disclosure states that the stablecoin is neither legal tender nor a bank deposit and has no FDIC or SIPC protection.

Kraken’s xStocks carry different access and ownership terms
Kraken’s tokenized stock vaults, introduced on Sep. 14, offered estimated net yields of 2% on SPYx and QQQx and 1.8% on NVDAx during the initial launch period. The products track two U.S.-listed funds and Nvidia shares.

Kraken said those tokens provide exposure to the referenced assets’ prices without the voting rights, dividend rights, or legal claims against the underlying companies associated with conventional share ownership. The vault service excluded residents of the United States, United Kingdom, Canada and Australia.

Its vault documentation described a three-day redemption process and risks including liquidation, smart-contract failures, liquidity shortages, bad debt and cross-chain transactions. Kraken warned that a stablecoin losing its peg or a custodian failing could reduce a user’s vault balance.

Separately, Payward’s Sep. 24 Ledger wallet partnership outlined hardware-wallet support for eligible xStocks customers. The companies planned deeper integration so users could buy, sell, and transfer tokens while holding their own keys.

Payward put cumulative xStocks transaction volume above $42 billion in that announcement. Its terms continued to exclude U.S. persons, and hardware-wallet support did not remove the jurisdictional restrictions. The September coverage distinguished holding tokens in a wallet from depositing them into a lending strategy.

Robinhood stock tokens use derivative contracts
Robinhood’s stock token terms describe its Classic Stock Tokens as derivative contracts under MiFID II. Holders receive exposure to a referenced asset’s price without owning the underlying shares or receiving voting rights, according to the company’s description.

Robinhood said the assets supporting those contracts were held through a U.S.-licensed institution. Its stock tokens remained unavailable to U.S. investors in the September coverage, despite referencing securities traded in American markets.

The same coverage reported approximately $44 million in Robinhood tokenized assets in a comparison that put Ondo at $857 million and xStocks at $487 million. Those figures described the assets in that comparison, rather than trading volume.

Securitize’s Oct. 8 release described possible future trading on NYSE and OKXICE venues, while its disclosures said neither venue had launched and access remained subject to approval and review. The company reserved the right to withdraw listings where needed or required.

In the latest close session, Petrobras (PBR - Free Report) was up +2.34% at $26.22. The stock exceeded the S&P 500, which registered a loss of 0.52% for the day. Elsewhere, the Dow saw a downswing of 1.24%, while the tech-heavy Nasdaq depreciated by 0.21%.

Prior to today's trading, shares of the oil and gas company had gained 22.94% outpaced the Oils-Energy sector's gain of 5.63% and the S&P 500's loss of 1.21%.

Investors will be eagerly watching for the performance of Petrobras in its upcoming earnings disclosure. The company's earnings report is set to be unveiled on November 10, 2026. It is anticipated that the company will report an EPS of $1.21, marking a 47.56% rise compared to the same quarter of the previous year. At the same time, our most recent consensus estimate is projecting a revenue of $31.84 billion, reflecting a 35.62% rise from the equivalent quarter last year.

Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $5.99 per share and revenue of $120.93 billion, indicating changes of +113.93% and +35.58%, respectively, compared to the previous year.

It is also important to note the recent changes to analyst estimates for Petrobras. Recent revisions tend to reflect the latest near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.

Research indicates that these estimate revisions are directly correlated with near-term share price momentum. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.

The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 24.53% upward. Petrobras presently features a Zacks Rank of #3 (Hold).

In terms of valuation, Petrobras is currently trading at a Forward P/E ratio of 4.28. Its industry sports an average Forward P/E of 7.69, so one might conclude that Petrobras is trading at a discount comparatively.

Also, we should mention that PBR has a PEG ratio of 2.29. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. As of the close of trade yesterday, the Oil and Gas - Integrated - International industry held an average PEG ratio of 0.7.

The Oil and Gas - Integrated - International industry is part of the Oils-Energy sector. This industry currently has a Zacks Industry Rank of 17, which puts it in the top 7% of all 250+ industries.

The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.

CoreWeave stock has been under pressure lately. Investors are concerned about the company's heavy debt load, plans for additional large capital expenditures to continue building out its artificial intelligence (AI) data center footprint, and surging interest expenses.

Making matters worse, the company is facing ramping competition in the neocloud space. Space Exploration Technologies (SPCX +1.89%) built its name around its reusable rocket technologies, orbital launch services, and its Starlink satellite communications network, but the company is also rapidly scaling its neocloud business. That could create additional pressures for CoreWeave.

Image source: Getty Images.

SpaceX has rapidly become a neocloud leader
SpaceX's recently published third-quarter report showed that sales for its artificial intelligence businesses surged 830% higher year over year to reach $7.56 billion. Meanwhile, its space segment's sales increased 6% to $1.77 billion, and its connectivity segment grew revenue by 69% to $5.25 billion. In other words, the company's AI businesses now generate more money than its space and connectivity segments combined.

SpaceX's AI revenue includes contributions from Grok and other sources, but the large majority of its segment sales in the quarter likely came from renting out compute to customers.

For comparison, CoreWeave posted revenue of roughly $2.58 billion. The company will likely see a substantial sequential quarterly sales increase, but SpaceX's neocloud business is likely generating substantially more revenue.

Extremely high demand means neocloud providers currently enjoy very strong pricing power, but that doesn't mean the space is immune to competitive dynamics. As the emerging powerhouse in the neocloud space, SpaceX has strong positioning that could eventually pressure CoreWeave. SpaceX also has much more solid financial footing, potentially giving it the ability to explore pricing options that would prove seriously problematic for CoreWeave.

SPCX Space Exploration Technologies$147.49+$2.74 (+1.89%)

NASDAQ · As of 4:00 PM ET 10/23/26

SpaceX's rise could make it harder for CoreWeave to secure the level of access to next-generation processors it wants from Nvidia. On the one hand, Nvidia's substantial stake in CoreWeave suggests that the neocloud specialist will remain a preferred customer. On the other hand, Nvidia actually holds a substantially larger position in SpaceX.

That doesn't necessarily mean Nvidia would deprioritize CoreWeave or divest its stock, but the graphics processing unit (GPU) leader also famously isn't wed to its investment positions -- having completely exited holdings in companies including Applied Digital and SoundHound AI in high-profile moves. If Nvidia finds itself weighing the significance of its relationship with CoreWeave against that with SpaceX, it's hard to imagine many scenarios in which the former comes out on top.

SpaceX's rise in the neocloud space doesn't necessarily mean CoreWeave is doomed, but it could create additional stress points that complicate the scaling and GPU lifecycle models used to suggest strong opportunities, despite the business's large debt load.

$20.93-$1.81 (-7.96%)

NYSE · As of 4:00 PM ET 10/23/26

AT&T (T -7.96%), a wireless and fiber telecom services provider, closed at $20.93, down 7.96%. Bloomberg's report on SpaceX's cell-site talks pressured the stock, and investors are now watching wireless competition and capital strategy.
Trading volume reached 84.6M shares, coming in about 88% above its three-month average of 45.1M shares.

How the markets moved todayS&P 500 (^GSPC -0.52%) fell 0.53% to 7,623, and the Nasdaq Composite (^IXIC -0.21%) slipped 0.21% to 25,955. In U.S. wireless telecommunications services and fiber broadband, Verizon Communications closed at $44.66, down 1.19%, while T-Mobile US fell 7.71% to $146.54 as concerns about carrier competition remained in focus.

What this means for investorsAT&T stock plunged after Bloomberg reported that Space Exploration Technologies is in negotiations to obtain access to around 80,000 cell sites, presumably to build America's fourth nationwide wireless network.

AT&T and its peers, Verizon and T-Mobile, have long operated on the premise that prospective new competitors would avoid entering the market due to the high likelihood of massive capital costs and low profit margins.

Now, SpaceX is blowing this theory out of the water. Additionally, with satellite coverage supplementing a terrestrial network, it would have a competitive advantage among customers who spend a lot of time in rural areas, likely placing further competitive pressure on AT&T.

T AT&T$20.93-$1.81 (-7.96%)

NYSE · As of 4:00 PM ET 10/23/26

These fears have also seemed to overshadow good news for AT&T. In its Oct. 21 earnings report, AT&T beat earnings estimates and raised its 2026 guidance. Additionally, NBT Bancorp bought 91,368 AT&T shares valued at around $2.23 million.

Admittedly, an added competitive challenge does not bode particularly well for AT&T. Nonetheless, AT&T provides a necessary service, and wireless customers tend to be sticky. Moreover, investors can buy AT&T stock now at an 11 P/E ratio and earn a 5.3% dividend yield, suggesting the Friday sell-off of the communication stock might be a buying opportunity.

Shares of membership-based warehouse retailer Costco Wholesale (COST -1.46%) trade near $1,010 as I write, nearly 8% under the record close of $1,094.32 they set on May 19.

The company behind the stock keeps delivering. Costco's earnings per share grew 14% in fiscal 2026 (the 52 weeks ending Aug. 30, 2026), faster than the 10% increase a year earlier. And net sales climbed 10% to around $297 billion.

What might $5,000 put in the stock now be worth by the end of 2030?

With a forecast based on earnings growth, a lower valuation multiple, and the dividend, I get around $6,350. It's a decent gain. But the same $5,000 in an index fund matching the long-term average of the S&P 500 (^GSPC -0.52%) might reach around $7,450.

Image source: Getty Images.

How fast can earnings grow?Costco's fiscal 2026 earnings included a one-time boost of $0.15 a share from tariff refunds in the fiscal fourth quarter. Without that, the company earned around $20.61 a share, still about 13% above fiscal 2025's $18.21.

Earnings per share were $11.27 in fiscal 2021, so this rate matches their average growth of around 13% a year for the last five years.

But the next few years likely won't match it. Costco hiked its yearly membership fees in the U.S. and Canada on Sept. 1, 2024, and it records that income gradually over each member's year. The higher fees made up around 30% of the 11% growth in membership fee revenue in fiscal 2026, according to Costco's annual report. By the fiscal fourth quarter, membership fee income was up only about 7% year over year.

That matters because membership fees brought in around $5.9 billion last fiscal year, or about half of Costco's $11.7 billion in operating income.

The rest of the business still has room to grow, of course. Comparable sales excluding gas prices and foreign exchange climbed 6.6% in fiscal 2026, and Costco plans to open up to 33 warehouses in fiscal 2027, including five relocations.

I'll assume earnings per share grow around 11% a year from here, a step down from the last five years but still a solid rate. That puts fiscal 2030 earnings per share at about $31.30.

Costco's valuation might come downThe price investors pay for these earnings arguably counts just as much. At around $1,010, Costco stock trades at about 49 times fiscal 2026 earnings. At the end of fiscal 2023, the stock fetched about 38 times that year's earnings of $14.16 per share.

I'll assume the price-to-earnings ratio lands at 40 times earnings by the end of 2030. That's still a premium price for a retailer, and I think it's fair for a business growing earnings roughly 11% a year.

At 40 times fiscal 2030 earnings of about $31.30, Costco stock would trade near $1,250. Now, $5,000 gets about 4.95 shares, so the stake might be worth around $6,190.

Costco also pays a dividend of $1.47 per share a quarter, after lifting it 13% in April. If the payout keeps climbing around 11% a year, in line with earnings, the 4.95 shares might collect a bit over $150 in regular dividends by the end of 2030 (I'm not counting any special dividends). That takes the total to around $6,350, a gain of about 6% a year.

COST Costco Wholesale$1,003.32-$14.89 (-1.46%)

NASDAQ · As of 4:00 PM ET 10/23/26

An index fund might do betterWith dividends, the S&P 500 has returned about 10% a year since 1928. At that rate, $5,000 put in the index through a fund on Oct. 23 could rise to about $7,450 by the end of 2030 -- about $1,100 more than my Costco forecast.

Then again, the market could return less than its long-run average in the next few years. And Costco's price-to-earnings ratio may not come down at all. The stock closed each of the last three fiscal years at more than 45 times earnings. But for Costco to keep up with the index fund, it'd have to trade at about 47 times earnings at the end of 2030, near where it trades today, while still growing earnings 11% a year.

Put another way, the company might do everything I'm assuming, and the stock could still trail the market if investors pay a bit less for every dollar Costco earns.

I think the warehouse club is still one of the best retailers to own for the long run, and I'd be comfortable adding shares slowly over time. But I wouldn't expect the stock to beat an index fund from here.

In the latest trading session, Intuit (INTU - Free Report) closed at $343.39, marking a -3.24% move from the previous day. The stock's performance was behind the S&P 500's daily loss of 0.52%. Meanwhile, the Dow experienced a drop of 1.24%, and the technology-dominated Nasdaq saw a decrease of 0.21%.

The stock of maker of TurboTax, QuickBooks and other accounting software has risen by 28.06% in the past month, leading the Computer and Technology sector's loss of 7.7% and the S&P 500's loss of 1.21%.

Analysts and investors alike will be keeping a close eye on the performance of Intuit in its upcoming earnings disclosure. The company is expected to report EPS of $2.47, down 26.05% from the prior-year quarter. Meanwhile, our latest consensus estimate is calling for revenue of $4.3 billion, up 10.81% from the prior-year quarter.

For the full year, the Zacks Consensus Estimates project earnings of $23.5 per share and a revenue of $23.39 billion, demonstrating changes of -3.17% and +9.07%, respectively, from the preceding year.

Investors might also notice recent changes to analyst estimates for Intuit. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.

Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.

The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 0.03% upward. Intuit is currently sporting a Zacks Rank of #2 (Buy).

In terms of valuation, Intuit is currently trading at a Forward P/E ratio of 15.1. For comparison, its industry has an average Forward P/E of 17.66, which means Intuit is trading at a discount to the group.

Also, we should mention that INTU has a PEG ratio of 1.15. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. As the market closed yesterday, the Computer - Software industry was having an average PEG ratio of 1.49.

The Computer - Software industry is part of the Computer and Technology sector. This industry, currently bearing a Zacks Industry Rank of 55, finds itself in the top 23% echelons of all 250+ industries.

The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

To follow INTU in the coming trading sessions, be sure to utilize Zacks.com.

Zacks' Research Chief Names "Stock Most Likely to Double"

Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.

This innovative software-as-a-service firm upped its user base +22% year over year. That rate is increasing and margins are expanding as AI efficiencies take effect. Of course, all our elite picks aren't winners, but this one could far surpass earlier Zacks' Stocks Set to Double like D-Wave Quantum, which shot up +680.1%.

Free: See Our Top Stock And 4 Runners Up